11 completed, 3 withdrawn, 2 terminated, 1 active not recruiting. 17 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 11, Withdrawn 3, Terminated 2, Active not recruiting 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow bavituximab: new trials by email Literature Review of bavituximab trials Research Report on bavituximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma Axitinib, Avelumab, Bavituximab - Hepatocellular Carcinoma | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 1 | 2022-11-04 | 2023-05-03 |
| 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck Bavituximab, Pembrolizumab - Squamous Cell Carcinoma | Phase 2 | Active not recruiting | University of Maryland, Baltimore | 7 | 2020-01-13 | 2026-02-19 |
| An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients Bavituximab, Pembrolizumab Injection - Gastric Cancer, GastroEsophageal Cancer | Phase 2 | Completed | OncXerna Theraputics, Inc. | 80 | 2019-09-11 | 2023-02-08 |
| A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Pembrolizumab, Bavituximab - Hepatocellular Carcinoma | Phase 2 | Completed | David Hsieh | 35 | 2018-04-26 | 2026-07-08 |
| Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma Temozolomide, Bavituximab, Radiation - Glioblastoma | Phase 2 | Completed | Massachusetts General Hospital | 36 | 2017-09-13 | 2024-05-16 |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer Bavituximab, Taxane - Breast Cancer, Triple Negative Breast Neoplasms | Phase 2 | Withdrawn | Peregrine Pharmaceuticals | 2016-03-01 | 2017-03-09 | |
| Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer durvalumab, bavituximab - Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Peregrine Pharmaceuticals | 2016-02-01 | 2016-08-01 | |
| Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer Bavituximab, Taxane - Metastatic Breast Cancer | Phase 2 / Phase 3 | Withdrawn | Peregrine Pharmaceuticals | 2015-12-01 | 2017-07-11 | |
| Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer Cabazitaxel plus bavituximab - Prostate Cancer, Prostatic Neoplasms | Phase 1 / Phase 2 | Terminated | Medical University of South Carolina | 4 | 2011-06-01 | 2018-07-13 |
| Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection Bavituximab, Pegylated interferon (PEG-IFN) - Hepatitis C | Phase 1 / Phase 2 | Completed | Peregrine Pharmaceuticals | 66 | 2011-01-01 | 2012-02-06 |
| Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer bavituximab, Gemcitabine - Metastatic Pancreatic Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 70 | 2011-01-01 | 2017-04-19 |
| Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 1 / Phase 2 | Completed | University of Texas Southwestern Medical Center | 47 | 2011-01-01 | 2020-11-12 |
| Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer Docetaxel plus bavituximab or placebo - Non-small-cell Lung Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 121 | 2010-06-01 | 2017-04-19 |
| Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer Paclitaxel / Carboplatin, bavituximab - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 86 | 2010-06-01 | 2017-04-19 |
| Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer Bavituximab - Carcinoma Breast Stage IV | Phase 2 | Completed | Peregrine Pharmaceuticals | 46 | 2008-07-01 | 2011-03-24 |
| Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer bavituximab plus paclitaxel and carboplatin - Non-small Cell Lung Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 49 | 2008-06-01 | 2011-03-24 |
| A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer Bavituximab - Breast Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 46 | 2008-01-01 | 2017-04-21 |
Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Hepatocellular (3) · Lung Neoplasms (2) · Carcinoma, Squamous Cell (1) · Fibrosis (1) · Gastrointestinal Neoplasms (1) · Glioblastoma (1) · Hepatitis (1) · Hepatitis C (1) · Liver Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Stomach Neoplasms (1)
Peregrine Pharmaceuticals (10) · University of Texas Southwestern Medical Center (2) · David Hsieh (1) · Massachusetts General Hospital (1) · Medical University of South Carolina (1) · OncXerna Theraputics, Inc. (1) · University of Maryland, Baltimore (1)
United States (11) · Georgia (4) · India (4) · Ukraine (3) · Russia (2) · South Korea (1) · Taiwan (1) · United Kingdom (1)
David Hsieh, MD (2) · Adam C Yopp, MD (1) · David Page, MD (1) · Elizabeth R Gerstner, MD (1) · Janet Nuttall, MPH (1) · Kathy Miller, MD (1) · Thomas Sklenar (1)
PMID 18784101, PMID 25236982, PMID 31429027, PMID 37327319, PMID 38467639, PMID 42346219
2015 (1), 2019 (1)